Advertisement
U.S. markets closed

CytomX Therapeutics Inc (6C1.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.8395+0.0280 (+3.45%)
At close: 09:31PM CET
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
126,617
101,214
53,163
37,312
68,427
Operating Expense
119,907
107,698
154,498
153,354
148,967
Operating Income
6,710
-6,484
-101,335
-116,042
-80,540
Net Non Operating Interest Income Expense
8,361
9,837
1,678
255
1,836
Other Income Expense
-10
-30
340
-83
-27
Pretax Income
15,061
3,323
-99,317
-115,870
-78,731
Tax Provision
1,231
3,892
0
0
-13,911
Net Income Common Stockholders
13,830
-569
-99,317
-115,870
-64,820
Diluted NI Available to Com Stockholders
13,830
-569
-99,317
-115,870
-64,820
Basic EPS
-0.15
-0.01
-1.51
-1.30
-1.40
Diluted EPS
-0.15
-0.01
-1.51
-1.30
-1.40
Basic Average Shares
69,945
73,808
65,740
64,147
46,146
Diluted Average Shares
69,945
73,808
65,740
64,147
46,146
Total Operating Income as Reported
6,710
-6,484
-101,335
-116,042
-80,540
Total Expenses
119,907
107,698
154,498
153,354
148,967
Net Income from Continuing & Discontinued Operation
13,830
-569
-99,317
-115,870
-64,820
Normalized Income
13,830
-569
-99,317
-115,870
-64,820
Interest Income
8,361
9,837
1,678
255
1,836
Interest Expense
-
-
-
-
-
Net Interest Income
8,361
9,837
1,678
255
1,836
EBIT
6,710
-6,484
-101,335
-116,042
-80,540
EBITDA
8,551
-4,309
-98,892
-113,336
-77,967
Reconciled Depreciation
1,841
2,175
2,443
2,706
2,573
Net Income from Continuing Operation Net Minority Interest
13,830
-569
-99,317
-115,870
-64,820
Normalized EBITDA
8,551
-4,309
-98,892
-113,336
-77,967
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0